2,638 results on '"Sehouli, Jalid"'
Search Results
2. Multimodal management of ectopic hepatic pregnancy: a systematic review of the literature
3. Cannabis use in endometriosis: the patients have their say—an online survey for German-speaking countries
4. Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic
5. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease
6. Correction: Accuracy of endometrial sampling in the diagnosis of endometrial cancer: a multicenter retrospective analysis of the JAGO-NOGGO
7. Accuracy of endometrial sampling in the diagnosis of endometrial cancer: a multicenter retrospective analysis of the JAGO-NOGGO
8. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
9. Training in obstetrics and gynecology between reality and vision: results of a JAGO–NOGGO survey in 601 physicians (NOGGO—Monitor-12 trial)
10. Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction
11. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication
12. Influence of appropriate emergency department utilization and verbal communication on physicians’ (dis)satisfaction with doctor–patient interactions with special consideration of migrational backgrounds
13. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
14. Pelvic floor hypertension: possible factors for pelvic floor tenderness in endometriosis patients—a pilot study
15. Interkulturelle Kompetenzen im Gesundheitswesen durch Fort- und Weiterbildungen fördern
16. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
17. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
18. Self-reported exhaustion and a 4-item physical frailty index to predict the incidence of major complications after onco-geriatric surgery
19. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium
20. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
21. A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany
22. Mechanisms of peripheral sensitization in endometriosis patients with peritoneal lesions and acyclical pain
23. Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study
24. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
25. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
26. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
27. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7
28. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
29. High-Performance-Teams – Krebschirurg trifft Hirnchirurg (Podcast: Weißbunt) : Prof. Dr. med. Dr. h.c. Jalid Sehouli, Direktor der Frauenklinik an der Berliner Charité, und Prof. Dr. Peter Vajkoczy, Neurochirurg, im Gespräch
30. Cancer
31. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
32. Genital tract microbiota composition profiles and use of prebiotics and probiotics in gynaecological cancer prevention: review of the current evidence, the European Society of Gynaecological Oncology prevention committee statement
33. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
34. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
35. Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey
36. Praktische Tipps für die Überbringung von schlechten und guten Nachrichten in der Medizin
37. Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
38. Perioperative advanced haemodynamic monitoring of patients undergoing multivisceral debulking surgery: an observational pilot study
39. ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer
40. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
41. Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas”
42. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer
43. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
44. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma
45. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
46. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
47. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
48. Umgang mit Wahrheit und Wahrhaftigkeit
49. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
50. Interprofessionelles und interkulturelles Arbeiten und Kommunikation in der Gesundheitsversorgung
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.